Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai

• Published in: BMC complementary and alternative medicine 2019-12, Vol.19 (1), p.357-13, Article 357
• Main Authors: Gao, Jiaming, Wang, Taiyi, Yao, Xi, Xie, Weiwei, Shi, Xianru, He, Shuang, Zhao, Tao, Wang, Chunhua, Zhu, Yan
• Format: Article
• Language: English
• Subjects: Adrenergic receptors; Animals; Arrhythmia; Autonomic nervous system; Bias; Bradycardia; Bradycardia - metabolism; Cardiac arrhythmia; Cardiomyocytes; Cardiovascular disease; Cell Line; Chinese medicine; Clinical trials; Collaboration; Coronary vessels; Drugs, Chinese Herbal - pharmacology; Electrocardiography; Experiments; Heart; Heart - drug effects; Heart rate; Herbal medicine; Immunofluorescence; Laboratory animals; Male; Meta-analysis; Myocytes, Cardiac - drug effects; Network analysis; Network pharmacology; Pharmacology; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-1 - metabolism; Shenxian-Shengmai oral liquid; Signal transduction; Software; Target recognition; Traditional Chinese medicine; Up-regulation; Up-Regulation - drug effects; β1-adrenergic signaling
• ISSN: 1472-6882; 1472-6882
• DOI: 10.1186/s12906-019-2769-0

Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM on bradycardia and to identify the possible active components and their pharmacological targets for this action. A literature-based meta-analysis was performed to evaluate the clinical efficacy of SXSM on bradycardia, which was confirmed by a rat ex vivo cardiac model. Network pharmacology analysis was then conducted to reveal the potential targets of SXSM active components and their anti-arrhythmia mechanisms. Finally, the identified drug-target interaction was confirmed by immunofluorescence assay in cardiomyocyte. Meta-analysis of the available clinical study data shows that Shenxian-Shengmai Oral Liquid has a favorable effect for bradycardia. In an ex vivo bradycardia model of rat heart, SXSM restored heart rate by affecting Heart rate variability (HRV) which is associated with autonomic nervous system activity. A drug-target-pathway network analysis connecting SXSM components with arrhythmia suggested that a prominent anti-arrhythmia mechanisms of SXSM was via β1-adrenergic signaling pathway, which was subsequently validated by immunofluorescence assay showing that SXSM indeed increased the expression of ADRB1 in cultured cardiomyocytes. By combining approaches of clinical evidence mining, experimental model confirmation, network pharmacology analyses and molecular mechanistic validation, we show that SXSM is an effective treatment for bradycardia and it involves multiple component interacting via multiple pathways, among which is the critical β1-adrenergic receptor upregulation. Our integrative approach could be applied to other multi-component traditional Chinese medicine investigation where ample clinical data are accumulated but advanced mechanistic studies are lacking.